Evogene Ltd Stock News

Conference call and webcast: today, May 21, 2025, 9:00 am ET Financial Highlights: In the first quarter of 2025, total revenues were approximately $2.4 million, compared to approximately $4.2 million in the first quarter of 2024. The first quarter of 2024 revenues included license fee payments totaling $3.5 million - $2.5 million from Lavie Bio's license fee under its collaboration with Corteva...

Zoom conference call scheduled for May 21, 2025, 9:00 AM ET REHOVOT, Israel , May 8, 2025 /PRNewswire/ -- May 8, 2025 - Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the first quarter of 2025, on Wednesday, May 21, 2025.

Lavie Bio improves agriculture productivity and sustainability through microbiome-based ag-biological products REHOVOT, Israel , April 21, 2025 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) a leading computational biology company focused on revolutionizing life-science-based product discovery and development, today announced the signing of a definitive agreement under which ICL, will...

Evogene Ltd. (NASDAQ:EVGN ) Q4 2024 Earnings Conference Call March 6, 2025 9:00 AM ET Company Participants Ofer Haviv - President and CEO Nir Nimrodi - Chairperson of the Board Yaron Eldad - Chief Financial Officer Operator Welcome to Evogene's Fourth Quarter Results Conference Call.

Conference call and webcast: today, March 6, 2025, 9:00 am ET Financial Highlights: In the year 2024, total revenues reached approximately $8.5 million compared to approximately $5.6 million in the year 2023. The increase in revenues is mainly due to increase in AgPlenus' revenues from its collaboration with Bayer and an increase in Casterra's seed sales.

Mr. Nir Nirmodi is Replacing Ms. Sarit Firon, who will Continue Serving as a Member of the Board REHOVOT, Israel , March 6, 2025 /PRNewswire/ -- Evogene Ltd.

Zoom conference call scheduled for March 6, 2025, 9:00 AM ET REHOVOT, Israel , Feb. 20, 2025 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the fourth quarter of 2024, on Thursday, March 6, 2025.

Initial fungicidally active compounds already discovered REHOVOT, Israel , Feb. 13, 2025 /PRNewswire/ -- AgPlenus Ltd., a global leader in designing and developing novel sustainable crop protection products and a subsidiary of Evogene Ltd.